Small molecule · Inhibitor of norepinephrine transporter (SLC6A2) · developed by Supernus Pharms
Viloxazine is a selective norepinephrine reuptake inhibitor that blocks the norepinephrine transporter, increasing norepinephrine signaling. It is studied in attention-deficit/hyperactivity disorder (ADHD) and in healthy lactating women.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 5, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06185985 | Phase 4 | Attention-Deficit/Hyperactivity Disorder | Completed | SUPN |
| NCT06259331 | Phase 4 | Healthy Lactating Women | Completed | SUPN |
| NCT01107496 | Phase 1/2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | SUPN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Attention-Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactivity Disorder (ADHD)Healthy Lactating Women
Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.
See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SUPN catalysts and pipeline →